Literature DB >> 21656131

Cytokine networks in glioma.

Kenichiro Iwami1, Atsushi Natsume, Toshihiko Wakabayashi.   

Abstract

Glioma is the most frequently occurring brain tumor, but the prognosis of patients with gliomas remains poor despite advances in surgery, radiotherapy, and chemotherapy. Therefore, great efforts have been made to develop improved therapeutic strategies. Cytokines are a heterogeneous group of soluble small polypeptides or glycoproteins that exert pleiotropic and redundant effects that promote the growth, differentiation, and activation of normal cells. Cytokines have either pro- or anti-inflammatory activity and immunosuppressive activity, depending on the microenvironment surrounding the tumor. The microenvironment consists of heterogeneous tumor cells, immune cells, and extracellular matrix. Modulation of the microenvironment by the tumor is essential for its growth and progress. Cytokine production acts as a means of communication in the tumor microenvironment. In this article, we review the cross-talk between cytokines in the tumor microenvironment and the cytokine therapies that have been used till date for glioma treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656131     DOI: 10.1007/s10143-011-0320-y

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  131 in total

1.  Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development.

Authors:  Nhu Nam Tran Thang; Madiha Derouazi; Géraldine Philippin; Séverine Arcidiaco; Wilma Di Berardino-Besson; Frédérick Masson; Sabine Hoepner; Cristina Riccadonna; Karim Burkhardt; Abhijit Guha; Pierre-Yves Dietrich; Paul R Walker
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.

Authors:  Sandeep Kunwar; Susan M Chang; Michael D Prados; Mitchel S Berger; John H Sampson; David Croteau; Jeffrey W Sherman; Amy Y Grahn; Vince S Shu; Jeanne L Dul; Syed R Husain; Bharat H Joshi; Christoph Pedain; Raj K Puri
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

3.  Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

Authors:  A E Sloan; R Dansey; L Zamorano; G Barger; C Hamm; F Diaz; R Baynes; G Wood
Journal:  Neurosurg Focus       Date:  2000-12-15       Impact factor: 4.047

4.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

Authors:  K W Moore; P Vieira; D F Fiorentino; M L Trounstine; T A Khan; T R Mosmann
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

5.  Type I interferons produced by dendritic cells promote their phenotypic and functional activation.

Authors:  Maria Montoya; Giovanna Schiavoni; Fabrizio Mattei; Ion Gresser; Filippo Belardelli; Persephone Borrow; David F Tough
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

6.  Intratumoral immunotherapy with interferon-alpha and interleukin-2 in glioblastoma.

Authors:  J Vaquero; R Martínez
Journal:  Neuroreport       Date:  1992-11       Impact factor: 1.837

7.  Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation.

Authors:  J Yoshida; Y Kajita; T Wakabayashi; K Sugita
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Expression of the histocompatibility glycoprotein HLA-DR in neurological disease.

Authors:  P L McGeer; S Itagaki; E G McGeer
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

9.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Authors:  M D Groves; V K Puduvalli; M R Gilbert; V A Levin; C A Conrad; V H Liu; K Hunter; C Meyers; K R Hess; W K Alfred Yung
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more
  23 in total

1.  Pediatric glioblastoma cells inhibit neurogenesis and promote astrogenesis, phenotypic transformation and migration of human neural progenitor cells within cocultures.

Authors:  Kurt Farrell; Gautam Mahajan; Parthasarathy Srinivasan; Moo-Yeal Lee; Chandrasekhar R Kothapalli
Journal:  Exp Cell Res       Date:  2017-11-10       Impact factor: 3.905

2.  Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma.

Authors:  David O Kamson; Tiffany J Lee; Kaushik Varadarajan; Natasha L Robinette; Otto Muzik; Pulak K Chakraborty; Michael Snyder; Geoffrey R Barger; Sandeep Mittal; Csaba Juhász
Journal:  J Nucl Med       Date:  2014-09-04       Impact factor: 10.057

3.  Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma.

Authors:  Liu Yang; Mei Liu; Chuanzong Deng; Zhikai Gu; Yilu Gao
Journal:  Tumour Biol       Date:  2012-04-29

4.  Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells.

Authors:  Kuan-Min Fang; Chung-Shi Yang; Tzu-Chien Lin; Ti-Chun Chan; Shun-Fen Tzeng
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

5.  Quantitative PET imaging of tryptophan accumulation in gliomas and remote cortex: correlation with tumor proliferative activity.

Authors:  Csaba Juhász; Diane C Chugani; Geoffrey R Barger; William J Kupsky; Pulak K Chakraborty; Otto Muzik; Sandeep Mittal
Journal:  Clin Nucl Med       Date:  2012-09       Impact factor: 7.794

6.  Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells.

Authors:  Liu Yang; Mei Liu; Zhikai Gu; Jianguo Chen; Yaohua Yan; Jian Li
Journal:  Tumour Biol       Date:  2012-08-23

Review 7.  Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.

Authors:  Mahmoud S Alghamri; Brandon L McClellan; Carson S Hartlage; Santiago Haase; Syed Mohd Faisal; Rohit Thalla; Ali Dabaja; Kaushik Banerjee; Stephen V Carney; Anzar A Mujeeb; Michael R Olin; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.988

8.  Regulation of Kir4.1 expression in astrocytes and astrocytic tumors: a role for interleukin-1 β.

Authors:  Emanuele Zurolo; Marjolein de Groot; Anand Iyer; Jasper Anink; Erwin A van Vliet; Jan J Heimans; Jaap C Reijneveld; Jan A Gorter; Eleonora Aronica
Journal:  J Neuroinflammation       Date:  2012-12-28       Impact factor: 8.322

9.  An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals.

Authors:  Mamatha B Nijaguna; Vikas Patil; Alangar S Hegde; Bangalore A Chandramouli; Arimappamagan Arivazhagan; Vani Santosh; Kumaravel Somasundaram
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

10.  Organotypic brain slices: a model to study the neurovascular unit micro-environment in epilepsies.

Authors:  Mélanie Morin-Brureau; Frédéric De Bock; Mireille Lerner-Natoli
Journal:  Fluids Barriers CNS       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.